Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
- Net revenue decreased by 10% in Q2'24 compared to Q2'23, excluding COVID-related revenue, net revenue increased by 8%.
- Net loss was $(204) million in Q2'24 compared to $81 million of net income in Q2'23.
- Adjusted EBITDA was $124 million in Q2'24, a 56% decrease from Q2'23.
- Catalent raised $600 million in term loans and had total available liquidity of ~$1.3 billion.
- Novo Holdings will acquire Catalent in an all-cash transaction valued at $16.5 billion.
- Net revenue decreased by 10% in Q2'24 compared to Q2'23.
- Net loss of $(204) million in Q2'24 compared to $81 million of net income in Q2'23.
- Adjusted EBITDA decreased by 56% in Q2'24 compared to Q2'23.
- Catalent's net leverage ratio increased to 10.3x as of December 31, 2023, compared to 7.6x at September 30, 2023.
- Catalent's total debt net of cash, cash equivalents, and marketable securities was $4.78 billion as of December 31, 2023.
Insights
The reported decline in Catalent's Q2'24 net revenue and significant net loss compared to the previous year's net income is a critical financial development, indicative of a substantial shift in the company's performance. The reduction in COVID-related revenue is a key factor behind these figures, reflecting a post-pandemic normalization that investors should take into account. The 8% revenue growth, when excluding COVID-related revenue, suggests underlying business strength that may be overshadowed by the headline figures. However, the 56% decrease in Adjusted EBITDA is concerning and may signal operational challenges or increased costs that could affect future profitability.
The announcement of the acquisition by Novo Holdings is a transformative event for Catalent. The $16.5 billion valuation represents a significant premium, likely reflecting Catalent's strategic value and growth prospects in the biologics and pharma sectors. This acquisition could provide Catalent with additional resources to invest in high-growth areas, potentially leading to long-term benefits for stakeholders. However, the increased debt levels and net leverage ratio, now at 10.3x, raise concerns about financial flexibility and the company's ability to manage its debt obligations effectively.
Assessing Catalent's performance within the broader pharmaceutical and biologics industry, the reported decrease in demand for COVID-19 related programs is consistent with industry trends as the urgency of the pandemic wanes. The growth in non-COVID sequential revenue in the Biologics and PCH segments, despite the overall decline, indicates resilience and potential for recovery in Catalent's core business areas. The strategic investment in operational improvements could position Catalent favorably as the market continues to evolve towards more personalized medicine and complex biologics, which are areas of high growth potential.
The acquisition by Novo Holdings should be closely monitored as it may lead to strategic shifts within Catalent. Investors and industry analysts will be interested in how this acquisition might affect Catalent's market positioning, particularly in relation to its competitors and the potential for expanded offerings in the pharma and biotech sectors.
From a legal and regulatory standpoint, Catalent's pending acquisition by Novo Holdings is subject to shareholder approval and regulatory clearances, which are standard conditions for such transactions. The absence of a financing contingency in the merger agreement suggests confidence in the deal's completion and the financial stability of the acquiring entity. However, the high leverage ratio could become a focal point for regulatory review, as it may raise questions about the long-term financial health of the combined entity. Stakeholders should consider the implications of the acquisition on contractual obligations and regulatory compliance, especially in the highly scrutinized pharmaceutical industry.
-
Q2'24 net revenue of
$1.03 billion 10% as reported, or11% in constant currency(1), compared to Q2'23.
-
Q2'24 net revenue, excluding COVID-related revenue of
~ in Q2’23 and$260 million ~ in Q2’24, increased$75 million 8% compared to Q2'23.
-
Q2'24 net loss of
$(204) million $81 million
-
Q2'24 Adjusted EBITDA(1) of
$124 million decreased56% as reported, or57% in constant currency, compared to Q2'23.
-
Raised
$600 million ~ in total available liquidity as of December 31, 2023.$1.3 billion
-
Announced on February 5, 2024 that Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at
$16.5 billion
(1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release.
“I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improvement initiatives and areas of high growth,” said Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc. “Our commitment to providing customers with premium development and manufacturing solutions is our north star and our recently announced transaction with Novo Holdings is further proof of that. With the benefit of Novo Holdings’ expanded resources, we will be able to accelerate investment in our business and enhance key offerings for current and prospective pharma and biotech customers. Indeed, we remain focused on continuing to serve our valued customers, as we always have.”
Second Quarter 2024 Consolidated Results
Net revenue of
Net loss and loss per basic and diluted share was
EBITDA (loss) from operations(1) was
Adjusted Net Loss(1) was
(1) |
See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. |
Second Quarter 2024 Segment Review
(Dollars in millions) |
Three Months Ended
|
|
Constant Currency |
|||||||
|
|
2023 |
|
|
|
2022 |
|
|
Change % |
|
Biologics |
|
|
|
|
|
|||||
Net revenue |
$ |
446 |
|
|
$ |
580 |
|
|
(24 |
) % |
Segment EBITDA |
|
39 |
|
|
|
181 |
|
|
(79 |
) % |
Segment EBITDA margin |
|
8.7 |
% |
|
|
31.3 |
% |
|
|
|
Pharma and Consumer Health |
|
|
|
|
|
|||||
Net revenue |
|
587 |
|
|
|
570 |
|
|
1 |
% |
Segment EBITDA |
|
126 |
|
|
|
135 |
|
|
(9 |
) % |
Segment EBITDA margin |
|
21.6 |
% |
|
|
23.7 |
% |
|
|
|
Inter-segment revenue elimination |
|
(1 |
) |
|
|
(1 |
) |
|
80 |
% |
Unallocated costs |
|
(159 |
) |
|
|
(52 |
) |
|
* |
|
Combined totals |
|
|
|
|
|
|||||
Net revenue |
$ |
1,032 |
|
|
$ |
1,149 |
|
|
(11 |
) % |
EBITDA from operations |
$ |
6 |
|
|
$ |
264 |
|
|
(98 |
) % |
* Not meaningful |
Biologics segment |
2023 vs. 2022 |
|
2023 vs. 2022 |
||||
Year-Over-Year Change |
Three Months Ended December 31, |
|
Six Months Ended December 31, |
||||
|
Net Revenue |
|
Segment
|
|
Net Revenue |
|
Segment
|
Organic |
(24) % |
|
(79) % |
|
(20) % |
|
(70) % |
Constant-currency change |
(24) % |
|
(79) % |
|
(20) % |
|
(70) % |
Foreign exchange translation impact on reporting |
1 % |
|
— % |
|
1 % |
|
— % |
Total % change |
(23) % |
|
(79) % |
|
(19) % |
|
(70) % |
Pharma and Consumer Health segment |
2023 vs. 2022 |
|
2023 vs. 2022 |
||||
Year-Over-Year Change |
Three Months Ended December 31, |
|
Six Months Ended December 31, |
||||
|
Net Revenue |
|
Segment EBITDA |
|
Net Revenue |
|
Segment EBITDA |
Organic |
1 % |
|
(9) % |
|
— % |
|
(13) % |
Impact of acquisitions |
— % |
|
— % |
|
3 % |
|
4 % |
Constant-currency change |
1 % |
|
(9) % |
|
3 % |
|
(9) % |
Foreign currency translation impact on reporting |
2 % |
|
3 % |
|
2 % |
|
3 % |
Total % change |
3 % |
|
(6) % |
|
5 % |
|
(6) % |
Segment Net Revenue as a % of Total Net Revenue
|
Three Months Ended |
||||||||
|
December 31,
|
|
September 30,
|
|
June 30,
|
|
March 31,
|
|
December 31,
|
Biologics |
44 % |
|
46 % |
|
38 % |
|
46 % |
|
50 % |
Pharma and Consumer Health |
56 % |
|
54 % |
|
62 % |
|
54 % |
|
50 % |
Net Revenue |
100 % |
|
100 % |
|
100 % |
|
100 % |
|
100 % |
Balance Sheet and Liquidity
During the second quarter, Catalent issued a new
As of December 31, 2023, Catalent had
Catalent's ratio of First Lien Debt over LTM Adjusted EBITDA was 4.8x at December 31, 2023. Catalent's senior secured credit agreement requires that this ratio remain below 6.5x.
Catalent’s net leverage ratio(1) as of December 31, 2023 was 10.3x, compared to 7.6x at September 30, 2023 and 3.8x as of December 31, 2022.
(1) |
See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. |
Merger Agreement with Novo Holdings
On February 5, 2024, Catalent announced that it had entered into a merger agreement pursuant to which Novo Holdings A/S, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, will acquire Catalent in an all-cash transaction that values Catalent at
In light of the pending merger with Novo Holdings, and as is customary during the pendency of such transactions, Catalent will not host an earnings conference call and will no longer provide forward-looking guidance.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in
Non-GAAP Financial Measures
Use of EBITDA from operations, Adjusted EBITDA, Adjusted Net Income and Segment EBITDA
Management measures operating performance based on consolidated earnings from operations before interest expense, expense (benefit) for income taxes, and depreciation and amortization, adjusted for the income or loss attributable to non-controlling interests (“EBITDA from operations”). EBITDA from operations is not defined under
Catalent believes that the presentation of EBITDA from operations enhances an investor’s understanding of its financial performance. Catalent believes this measure is a useful financial metric to assess its operating performance across periods by excluding certain items that it believes are not representative of its core business and uses this measure for business planning purposes.
In addition, given the significant investments that Catalent has made in the past in property, plant and equipment, depreciation and amortization expenses represent a meaningful portion of its cost structure. Catalent believes that EBITDA from operations will provide investors with a useful tool for assessing the comparability between periods of Catalent's ability to generate cash from operations sufficient to pay taxes, to service debt and to undertake capital expenditures because it eliminates depreciation and amortization expense. Catalent presents EBITDA from operations in order to provide supplemental information that it considers relevant for the readers of its consolidated financial statements, and such information is not meant to replace or supersede
Catalent evaluates the performance of its segments based on segment earnings before non-controlling interest, other (income) expense, impairments, restructuring costs, interest expense, income tax expense (benefit), and depreciation and amortization (“segment EBITDA”). Moreover, under Catalent’s credit agreement, its ability to engage in certain activities, such as incurring certain additional indebtedness, making certain investments and paying certain dividends, is tied to ratios based on Adjusted EBITDA, which is not defined under
Management also measures operating performance based on Adjusted Net Income and Adjusted Net Income per share. Adjusted Net Income is not defined under
The most directly comparable
Catalent does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable
Use of Constant Currency
As changes in exchange rates are an important factor in understanding period-to-period comparisons, Catalent believes the presentation of results on a constant-currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant-currency information compares results between periods as if exchange rates had remained constant period over period. Catalent uses results on a constant-currency basis as one measure to evaluate its performance. Catalent calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. Catalent generally refers to such amounts calculated on a constant-currency basis as excluding the impact of foreign exchange or being on a constant-currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with
Forward-Looking Statements
This release contains both historical and forward-looking statements and guidance. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe Catalent’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalent’s expectations, projections, and guidance. Some of the factors that could cause actual results to differ include, but are not limited to, the following: the completion of Catalent’s closing procedures, including without limitation its evaluation of the effectiveness of its internal controls over financial reporting; Catalent’s ability to resolve productivity issues at three of its manufacturing facilities, the impact of such issues on product made at these facilities, the timing of recovering unproduced batches and resumption of normal activities at these facilities, and the impact of such issues on Catalent’s results of operations and financial condition; the declining demand for various vaccines and treatments for the SARS-Co-V-2 strain of coronavirus and its variants (“COVID-19”) from both patients and governments around the world may affect sales of the COVID-19 products Catalent manufactures; participation in a highly competitive market and increased competition that may adversely affect Catalent’s business; demand for its offerings, which depends in part on its customers’ research and development and the clinical and market success of their products; product and other liability risks that could adversely affect Catalent’s results of operations, financial condition, liquidity and cash flows; failure to comply with existing and future regulatory requirements; failure to provide quality offerings to customers could have an adverse effect on Catalent’s business and subject it to regulatory actions and costly litigation; problems providing the highly exacting and complex services or support required; global economic, political and regulatory risks to Catalent’s operations, including risks from inflation, disruptions to global supply chains, or from the Ukrainian-Russian war; inability to enhance existing or introduce new technology or service offerings in a timely manner; inadequate patents, copyrights, trademarks and other forms of intellectual property protections; fluctuations in the costs, availability, and suitability of the components of the products Catalent manufactures, including active pharmaceutical ingredients, excipients, purchased components and raw materials; changes in market access or healthcare reimbursement in
Important risk factors relating to the pending merger with Novo Holdings that also may cause a difference between actual results and forward-looking statements include, but are not limited to: (i) the completion of the merger on anticipated terms and timing, including obtaining required stockholder and regulatory approvals, and the satisfaction of other conditions to the completion of the merger; (ii) potential litigation relating to the merger that could be instituted by or against Catalent, Novo Holdings or their respective affiliates, directors or officers, including the effects of any outcomes related thereto; (iii) the risk that disruptions from the merger will harm Catalent’s business, including current plans and operations; (iv) the ability of Catalent to retain and hire key personnel; (v) potential adverse reactions or changes to business or governmental relationships resulting from the announcement or completion of the merger; (vi) continued availability of capital and financing and rating agency actions; (vii) legislative, regulatory and economic developments affecting Catalent’s business; (viii) general economic and market developments and conditions; (ix) certain restrictions during the pendency of the merger that may impact Catalent’s ability to pursue certain business opportunities or strategic transactions; (x) unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as Catalent’s response to any of the aforementioned factors; (xi) significant transaction costs associated with the merger; (xii) the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (xiii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger, including in circumstances requiring Catalent to pay a termination fee or other expenses; (xiv) competitive responses to the merger; (xv) Catalent’s management response to any of the aforementioned factors; (xvi) the risks and uncertainties pertaining to Catalent’s business, including those set forth in Catalent’s most recent Annual Report on Form 10-K and Catalent’s subsequent Quarterly Reports on Form 10-Q, as such risk factors may be amended, supplemented or superseded from time to time by other reports filed or furnished by Catalent with the SEC; and (xvii) the risks and uncertainties that will be described in the proxy statement that will be filed in connection with the merger. These risks, as well as other risks associated with the merger, will be more fully discussed in the proxy statement. While the list of factors presented here is, and the list of factors to be presented in the proxy statement will be, considered representative, no such list should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material impact on Catalent’s financial condition, results of operations, credit rating or liquidity.
These forward-looking statements speak only as of the date of this release or as of the date they are made, and Catalent does not undertake to and specifically disclaims any obligation to publicly release the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
More products. Better treatments. Reliably supplied.™
Catalent, Inc. |
||||||||||||||||||
Consolidated Statements of Operations |
||||||||||||||||||
(Unaudited; dollars and shares in millions, except per share data) |
||||||||||||||||||
|
Three Months Ended
|
|
FX Impact |
|
Constant Currency
|
|||||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
|
Change $ |
|
Change % |
|||||
Net revenue |
$ |
1,032 |
|
|
$ |
1,149 |
|
|
$ |
14 |
|
|
$ |
(131 |
) |
|
(11 |
) % |
Cost of sales |
|
871 |
|
|
|
762 |
|
|
|
12 |
|
|
|
97 |
|
|
13 |
% |
Gross margin |
|
161 |
|
|
|
387 |
|
|
|
2 |
|
|
|
(228 |
) |
|
(59 |
) % |
Selling, general, and administrative expenses |
|
239 |
|
|
|
226 |
|
|
|
1 |
|
|
|
12 |
|
|
6 |
% |
Goodwill impairment adjustments |
|
(2 |
) |
|
|
— |
|
|
|
— |
|
|
|
(2 |
) |
|
* |
|
Other operating expense, net |
|
35 |
|
|
|
23 |
|
|
|
1 |
|
|
|
11 |
|
|
39 |
% |
Operating (loss) earnings |
|
(111 |
) |
|
|
138 |
|
|
|
— |
|
|
|
(249 |
) |
|
* |
|
Interest expense, net |
|
66 |
|
|
|
47 |
|
|
|
1 |
|
|
|
18 |
|
|
39 |
% |
Other expense (income), net |
|
4 |
|
|
|
(23 |
) |
|
|
(1 |
) |
|
|
28 |
|
|
* |
|
(Loss) earnings before income taxes |
|
(181 |
) |
|
|
114 |
|
|
|
— |
|
|
|
(295 |
) |
|
* |
|
Income tax expense |
|
23 |
|
|
|
33 |
|
|
|
(1 |
) |
|
|
(9 |
) |
|
(28 |
) % |
Net (loss) income |
$ |
(204 |
) |
|
$ |
81 |
|
|
$ |
1 |
|
|
$ |
(286 |
) |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Weighted average shares outstanding – basic |
|
182 |
|
|
|
181 |
|
|
|
|
|
|
|
|||||
Weighted average shares outstanding – diluted |
|
182 |
|
|
|
181 |
|
|
|
|
|
|
|
|||||
|
|
|
|
|
|
|
|
|
|
|||||||||
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|||||||||
Basic |
|
|
|
|
|
|
|
|
|
|||||||||
Net (loss) earnings |
$ |
(1.12 |
) |
|
$ |
0.45 |
|
|
|
|
|
|
|
|||||
Diluted |
|
|
|
|
|
|
|
|
|
|||||||||
Net (loss) earnings |
$ |
(1.12 |
) |
|
$ |
0.44 |
|
|
|
|
|
|
|
|||||
* |
Not meaningful |
Catalent, Inc. |
||||||||||||||||
Consolidated Statements of Operations |
||||||||||||||||
(Unaudited; dollars and shares in millions, except per share data) |
||||||||||||||||
|
Six Months Ended
|
|
FX impact |
|
Constant Currency
|
|||||||||||
|
|
2023 |
|
|
|
2022 |
|
|
|
Change $ |
|
Change % |
||||
Net revenue |
$ |
2,014 |
|
|
$ |
2,171 |
|
$ |
33 |
|
$ |
(190 |
) |
|
(9 |
) % |
Cost of sales |
|
1,684 |
|
|
|
1,526 |
|
|
25 |
|
$ |
133 |
|
|
9 |
% |
Gross margin |
|
330 |
|
|
|
645 |
|
|
8 |
|
$ |
(323 |
) |
|
(50 |
) % |
Selling, general and administrative expenses |
|
444 |
|
|
|
422 |
|
|
4 |
|
$ |
18 |
|
|
4 |
% |
Goodwill impairment charges |
|
687 |
|
|
|
— |
|
|
— |
|
$ |
687 |
|
|
* |
|
Other operating expense |
|
36 |
|
|
|
25 |
|
|
— |
|
$ |
11 |
|
|
35 |
% |
Operating (loss) earnings |
|
(837 |
) |
|
|
198 |
|
|
4 |
|
$ |
(1,039 |
) |
|
* |
|
Interest expense, net |
|
124 |
|
|
|
79 |
|
|
1 |
|
$ |
44 |
|
|
56 |
% |
Other expense, net |
|
17 |
|
|
|
2 |
|
|
3 |
|
$ |
12 |
|
|
* |
|
(Loss) earnings before taxes |
|
(978 |
) |
|
|
117 |
|
|
— |
|
$ |
(1,095 |
) |
|
* |
|
Income tax (benefit) expense |
|
(15 |
) |
|
|
36 |
|
|
— |
|
$ |
(51 |
) |
|
(142 |
) % |
Net (loss) earnings |
$ |
(963 |
) |
|
$ |
81 |
|
$ |
— |
|
$ |
(1,044 |
) |
|
* |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Weighted average shares outstanding – basic |
|
181 |
|
|
|
180 |
|
|
|
|
|
|
||||
Weighted average shares outstanding – diluted |
|
181 |
|
|
|
181 |
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|||||||
Earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|||||||
Basic |
|
|
|
|
|
|
|
|
|
|||||||
Net (loss) earnings |
$ |
(5.31 |
) |
|
$ |
0.45 |
|
|
|
|
|
|
||||
Diluted |
|
|
|
|
|
|
|
|
|
|||||||
Net (loss) earnings |
$ |
(5.31 |
) |
|
$ |
0.45 |
|
|
|
|
|
|
||||
Catalent, Inc. |
|||||
Condensed Consolidated Balance Sheets |
|||||
(Unaudited; dollars in millions) |
|||||
|
December 31, 2023 |
|
June 30, 2023 |
||
ASSETS |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
229 |
|
$ |
280 |
Trade receivables, net |
|
832 |
|
|
1,002 |
Inventories |
|
775 |
|
|
777 |
Prepaid expenses and other |
|
742 |
|
|
633 |
Total current assets |
|
2,578 |
|
|
2,692 |
Property, plant, and equipment, net |
|
3,777 |
|
|
3,682 |
Other non-current assets, including intangible assets |
|
3,641 |
|
|
4,403 |
Total assets |
$ |
9,996 |
|
$ |
10,777 |
|
|
|
|
||
LIABILITIES AND SHAREHOLDERS' EQUITY |
|||||
Current liabilities: |
|
|
|
||
Current portion of long-term obligations and other short-term borrowings |
$ |
46 |
|
$ |
536 |
Accounts payable |
|
407 |
|
|
424 |
Other accrued liabilities |
|
589 |
|
|
570 |
Total current liabilities |
|
1,042 |
|
|
1,530 |
Long-term obligations, less current portion |
|
4,959 |
|
|
4,313 |
Other non-current liabilities |
|
306 |
|
|
323 |
Total shareholders' equity |
|
3,689 |
|
|
4,611 |
Total liabilities and shareholders' equity |
$ |
9,996 |
|
$ |
10,777 |
Catalent, Inc. |
|||||||
Condensed Consolidated Statements of Cash Flows |
|||||||
(Unaudited; dollars in millions) |
|||||||
|
Six Months Ended December 31, |
||||||
|
|
2023 |
|
|
|
2022 |
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
||||
Net cash provided by operating activities |
$ |
42 |
|
|
$ |
122 |
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
||||
Acquisition of property, equipment, and other productive assets |
|
(178 |
) |
|
|
(317 |
) |
Proceeds from maturity of marketable securities |
|
— |
|
|
|
61 |
|
Proceeds from sale of property and equipment |
|
1 |
|
|
|
7 |
|
Payment for acquisitions, net of cash acquired |
|
— |
|
|
|
(474 |
) |
Payment for investments |
|
(2 |
) |
|
|
(1 |
) |
Net cash used in investing activities |
|
(179 |
) |
|
|
(724 |
) |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
||||
Proceeds from borrowing |
|
815 |
|
|
|
625 |
|
Payments related to long-term obligations |
|
(722 |
) |
|
|
(32 |
) |
Financing fees paid |
|
(16 |
) |
|
|
(4 |
) |
Exercise of stock options |
|
1 |
|
|
|
1 |
|
Other financing activities |
|
6 |
|
|
|
7 |
|
Net cash provided by financing activities |
|
84 |
|
|
|
597 |
|
Effect of foreign currency exchange on cash and cash equivalents |
|
2 |
|
|
|
(2 |
) |
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
(51 |
) |
|
|
(7 |
) |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD |
|
280 |
|
|
|
449 |
|
CASH AND CASH EQUIVALENTS AT END OF PERIOD |
$ |
229 |
|
|
$ |
442 |
|
Catalent, Inc. |
|||||||||||||||||||
Reconciliation of Net Earnings (Loss) to EBITDA from Operations and Adjusted EBITDA* |
|||||||||||||||||||
(Unaudited; dollars in millions) |
|||||||||||||||||||
|
Three months ended |
||||||||||||||||||
|
December 31,
|
|
March 31,
|
|
June 30,
|
|
September 30,
|
|
December 31,
|
||||||||||
Net earnings (loss) |
$ |
81 |
|
|
$ |
(227 |
) |
|
$ |
(110 |
) |
|
$ |
(759 |
) |
|
$ |
(204 |
) |
Interest expense, net |
|
47 |
|
|
|
51 |
|
|
|
56 |
|
|
|
58 |
|
|
|
66 |
|
Income tax expense (benefit) |
|
33 |
|
|
|
(55 |
) |
|
|
(67 |
) |
|
|
(38 |
) |
|
|
23 |
|
Depreciation and amortization |
|
103 |
|
|
|
106 |
|
|
|
114 |
|
|
|
112 |
|
|
|
121 |
|
EBITDA (loss) from operations |
|
264 |
|
|
|
(125 |
) |
|
|
(7 |
) |
|
|
(627 |
) |
|
|
6 |
|
Goodwill impairment charges |
|
— |
|
|
|
210 |
|
|
|
— |
|
|
|
689 |
|
|
|
(2 |
) |
Stock-based compensation |
|
10 |
|
|
|
6 |
|
|
|
— |
|
|
|
19 |
|
|
|
16 |
|
Impairment charges and gain/loss on sale of assets |
|
1 |
|
|
|
6 |
|
|
|
93 |
|
|
|
(1 |
) |
|
|
15 |
|
Restructuring costs |
|
23 |
|
|
|
9 |
|
|
|
30 |
|
|
|
2 |
|
|
|
17 |
|
Acquisition, integration, and other special items |
|
9 |
|
|
|
8 |
|
|
|
9 |
|
|
|
7 |
|
|
|
11 |
|
Foreign exchange (gain) loss |
|
(26 |
) |
|
|
(8 |
) |
|
|
(4 |
) |
|
|
9 |
|
|
|
2 |
|
Site transformation costs |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14 |
|
|
|
16 |
|
Pension settlement charges |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3 |
|
Impacts from COVID-19 contract settlement |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
Fire loss contingency |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
Other adjustments |
|
2 |
|
|
|
(1 |
) |
|
|
1 |
|
|
|
— |
|
|
|
7 |
|
Adjusted EBITDA |
$ |
283 |
|
|
$ |
105 |
|
|
$ |
122 |
|
|
$ |
112 |
|
|
$ |
124 |
|
Favorable (unfavorable) FX impact |
|
|
|
|
|
|
|
|
|
2 |
|
||||||||
Adjusted EBITDA at constant currency |
|
|
|
|
|
|
|
|
$ |
122 |
|
||||||||
* |
Refer to Catalent's description of non-GAAP measures, including EBITDA from operations and Adjusted EBITDA as referenced above. |
Catalent, Inc. |
|||||||||||||||||||
Reconciliation of Net Loss to Adjusted Net (Loss) Income* |
|||||||||||||||||||
(Unaudited; dollars in millions, except per share data) |
|||||||||||||||||||
|
Three months ended |
||||||||||||||||||
|
December 31,
|
|
March 31,
|
|
June 30,
|
|
September 30,
|
|
December 31, 2023 |
||||||||||
Net earnings (loss) |
$ |
81 |
|
|
$ |
(227 |
) |
|
$ |
(110 |
) |
|
$ |
(759 |
) |
|
$ |
(204 |
) |
Amortization (1) |
|
34 |
|
|
|
34 |
|
|
|
35 |
|
|
|
34 |
|
|
|
33 |
|
Goodwill impairment charges (2) |
|
— |
|
|
|
210 |
|
|
|
— |
|
|
|
689 |
|
|
|
(2 |
) |
Stock-based compensation |
|
10 |
|
|
|
6 |
|
|
|
— |
|
|
|
19 |
|
|
|
16 |
|
Impairment charges and gain/loss on sale of assets (3) |
|
1 |
|
|
|
6 |
|
|
|
93 |
|
|
|
(1 |
) |
|
|
15 |
|
Restructuring costs (4) |
|
23 |
|
|
|
9 |
|
|
|
30 |
|
|
|
2 |
|
|
|
17 |
|
Acquisition, integration, and other special items (5) |
|
9 |
|
|
|
8 |
|
|
|
9 |
|
|
|
7 |
|
|
|
11 |
|
Foreign exchange (gain) loss |
|
(26 |
) |
|
|
(8 |
) |
|
|
(4 |
) |
|
|
9 |
|
|
|
2 |
|
Site transformation costs (6) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
14 |
|
|
|
16 |
|
Pension settlement charges (7) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
3 |
|
Impacts from COVID-19 contract settlement (8) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
Fire loss contingency (9) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
Other adjustments (10) |
|
2 |
|
|
|
— |
|
|
|
— |
|
|
|
(1 |
) |
|
|
7 |
|
Estimated tax effect of adjustments (11) |
|
(12 |
) |
|
|
(12 |
) |
|
|
(83 |
) |
|
|
(21 |
) |
|
|
13 |
|
Discrete income tax benefit items (12) |
|
— |
|
|
|
(43 |
) |
|
|
31 |
|
|
|
(16 |
) |
|
|
(3 |
) |
Adjusted net income (loss) (ANI) |
$ |
122 |
|
|
$ |
(17 |
) |
|
$ |
1 |
|
|
$ |
(24 |
) |
|
$ |
(43 |
) |
|
|
|
|
|
|
|
|
|
|
||||||||||
Weighted average shares outstanding – basic |
|
181 |
|
|
|
|
|
|
|
|
|
182 |
|
||||||
Weighted average shares outstanding – diluted |
|
181 |
|
|
|
|
|
|
|
|
|
182 |
|
||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
Earnings per share: |
|
|
|
|
|
|
|
|
|
||||||||||
Net earnings (loss) per share – basic |
$ |
0.45 |
|
|
|
|
|
|
|
|
$ |
(1.12 |
) |
||||||
Net earnings (loss) per share – diluted |
$ |
0.44 |
|
|
|
|
|
|
|
|
$ |
(1.12 |
) |
||||||
|
|
|
|
|
|
|
|
|
|
||||||||||
ANI per share: |
|
|
|
|
|
|
|
|
|
||||||||||
ANI (loss) per share – basic |
$ |
0.67 |
|
|
|
|
|
|
|
|
$ |
(0.24 |
) |
||||||
ANI (loss) per share – diluted (13) |
$ |
0.67 |
|
|
|
|
|
|
|
|
$ |
(0.24 |
) |
||||||
* |
Refer to Catalent's description of non-GAAP measures, including Adjusted Net Income (Loss) as referenced above. |
|||
|
(1) |
Represents the amortization attributable to purchase accounting for previously completed business combinations. |
||
|
(2) |
Non-cash goodwill impairment charges during the three months ended March 31, 2023 were associated with the Company's Consumer Health reporting unit. Non-cash goodwill impairment charges during the three months ended September 30, 2023 were associated with the Company's Biomodalities and Consumer Health reporting units. |
||
|
(3) |
For the three months ended June 30, 2023, represents fixed asset impairment charges primarily associated with an idle facility in the Biologics segment. Impairment charges and gain/loss on sale of assets for the three ended December 31, 2023 includes fixed asset impairment charges associated with equipment for a product with significant decline demand in the Company's Biologics segment. |
||
|
(4) |
Restructuring costs represent employee and non-employee restructuring charges associated with Catalent's plans to reduce costs, consolidate facilities, and optimize its infrastructure across the organization. |
||
|
(5) |
Acquisition, integration and other special items include costs associated with its October 2022 acquisition of Metrics Contract Services. |
||
|
(6) |
For the three months ended September 30, 2023 and December 31, 2023, represents operational and engineering enhancements and costs related to a transformation program in our Biologics segment. |
||
|
(7) |
Represents the loss on partial settlement of a frozen domestic qualified pension plan. |
||
|
(8) |
For the three months ended December 31, 2023, represents one-time inventory charges for the settlement of a COVID-19 agreement where revenue from the settlement was deferred into future periods, a majority of which is expected within fiscal year 2024. |
||
|
(9) |
For the three months ended December 31, 2023, represents one-time loss contingency accruals for inventory and damages sustained from a fire at a facility in our Biologics segment. |
||
|
(10) |
For the three months ended December 31, 2023, primarily represents one-time charges of penalties and interest on a value-added tax settlement in |
||
|
(11) |
The tax effect of adjustments to Adjusted Net (Loss) Income is computed by applying the statutory tax rate in the jurisdictions to the income or expense items that are adjusted in the period presented; if a valuation allowance exists, the rate applied is zero. |
||
|
(12) |
Discrete period income tax expense items are unusual or infrequently occurring items, primarily including: changes in judgment related to the realizability of deferred tax assets in future years, changes in measurement of a prior-year tax position, deferred tax impact of changes in tax law, and purchase accounting. |
||
|
(13) |
For the three months ended December 31, 2023 and 2022, represents Adjusted Net (Loss) Income divided by the weighted average sum of fully diluted shares outstanding, which is equal to (a) the number of shares of common stock outstanding, plus (b) the number of shares of its common stock that would be issued assuming exercise or vesting of all potentially dilutive instruments. For the three months ended December 31, 2023 and 2022, the weighted average number of shares was 182 million and 181 million, respectively. |
||
Catalent, Inc. |
|||||||||||||||
Reconciliation of Segment EBITDA to Net Loss |
|||||||||||||||
(Unaudited; dollars in millions, except per share data) |
|||||||||||||||
|
Three Months Ended December 31, |
|
Six Months Ended December 31, |
||||||||||||
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
|
Biologics Segment EBITDA |
$ |
39 |
|
|
$ |
181 |
|
|
$ |
88 |
|
|
$ |
294 |
|
Pharma and Consumer Health Segment EBITDA |
|
126 |
|
|
|
135 |
|
|
|
227 |
|
|
|
243 |
|
Sub-Total |
$ |
165 |
|
|
$ |
316 |
|
|
$ |
315 |
|
|
$ |
537 |
|
Reconciling items to net loss |
|
|
|
|
|
|
|
||||||||
Unallocated costs (1) |
$ |
(159 |
) |
|
$ |
(52 |
) |
|
|
(936 |
) |
|
|
(139 |
) |
Depreciation and amortization |
|
(121 |
) |
|
|
(103 |
) |
|
|
(233 |
) |
|
|
(202 |
) |
Interest expense, net |
|
(66 |
) |
|
|
(47 |
) |
|
|
(124 |
) |
|
|
(79 |
) |
Income tax expense |
|
(23 |
) |
|
|
(33 |
) |
|
|
15 |
|
|
|
(36 |
) |
Net (loss) earnings |
$ |
(204 |
) |
|
$ |
81 |
|
|
$ |
(963 |
) |
|
$ |
81 |
|
(1) |
Unallocated costs include restructuring and special items, stock-based compensation, impairment charges, gain on sale of subsidiary, certain other corporate directed costs, and other costs that are not allocated to the segments. |
Catalent, Inc. |
|||||||||||||||||||
Calculation of Net Leverage Ratio |
|||||||||||||||||||
(Unaudited; dollars in millions) |
|||||||||||||||||||
|
December 31,
|
|
March 31,
|
|
June 30,
|
|
September 30,
|
|
December 31,
|
||||||||||
Incremental Term Loan B-3, due 2028 |
$ |
1,426 |
|
|
$ |
1,422 |
|
|
$ |
1,418 |
|
|
$ |
1,415 |
|
|
$ |
1,411 |
|
Incremental Term Loan B-4, due 2028 |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
600 |
|
Revolving credit facility |
|
600 |
|
|
|
550 |
|
|
|
500 |
|
|
|
585 |
|
|
|
— |
|
Unamortized discount and debt issuance costs |
|
(13 |
) |
|
|
(12 |
) |
|
|
(11 |
) |
|
|
(12 |
) |
|
|
(25 |
) |
Total Secured Debt |
|
2,013 |
|
|
|
1,960 |
|
|
|
1,907 |
|
|
|
1,988 |
|
|
|
1,986 |
|
Senior Notes, due 2027, |
|
500 |
|
|
|
500 |
|
|
|
500 |
|
|
|
500 |
|
|
|
500 |
|
Senior Notes, due 2028 (EUR), |
|
879 |
|
|
|
895 |
|
|
|
904 |
|
|
|
872 |
|
|
|
910 |
|
Senior Notes, due 2029, |
|
550 |
|
|
|
550 |
|
|
|
550 |
|
|
|
550 |
|
|
|
550 |
|
Senior Notes due 2030, |
|
650 |
|
|
|
650 |
|
|
|
650 |
|
|
|
650 |
|
|
|
650 |
|
Finance Leases / Other |
|
291 |
|
|
|
323 |
|
|
|
366 |
|
|
|
412 |
|
|
|
434 |
|
Unamortized discount and debt issuance costs |
|
(30 |
) |
|
|
(29 |
) |
|
|
(28 |
) |
|
|
(26 |
) |
|
|
(25 |
) |
Total Unsecured Debt |
|
2,840 |
|
|
|
2,889 |
|
|
|
2,942 |
|
|
|
2,958 |
|
|
|
3,019 |
|
Total Debt |
|
4,853 |
|
|
|
4,849 |
|
|
|
4,849 |
|
|
|
4,946 |
|
|
|
5,005 |
|
Cash and Cash Equivalents |
|
442 |
|
|
|
252 |
|
|
|
280 |
|
|
|
209 |
|
|
|
229 |
|
Marketable Securities |
|
28 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total Net Debt |
$ |
4,383 |
|
|
$ |
4,597 |
|
|
$ |
4,569 |
|
|
$ |
4,737 |
|
|
$ |
4,776 |
|
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
||||||||||
Q3 2022 |
|
339 |
|
|
|
|
|
|
|
|
|
||||||||
Q4 2022 |
|
358 |
|
|
|
358 |
|
|
|
|
|
|
|
||||||
Q1 2023 |
|
187 |
|
|
|
187 |
|
|
|
187 |
|
|
|
|
|
||||
Q2 2023 |
|
283 |
|
|
|
283 |
|
|
|
283 |
|
|
|
283 |
|
|
|
||
Q3 2023 |
|
|
|
105 |
|
|
|
105 |
|
|
|
105 |
|
|
|
105 |
|
||
Q4 2023 |
|
|
|
|
|
122 |
|
|
|
122 |
|
|
|
122 |
|
||||
Q1 2024 |
|
|
|
|
|
|
|
112 |
|
|
|
112 |
|
||||||
Q2 2024 |
|
|
|
|
|
|
|
|
124 |
|
|||||||||
LTM Adjusted EBITDA |
$ |
1,167 |
|
|
$ |
933 |
|
|
$ |
697 |
|
|
$ |
622 |
|
|
$ |
463 |
|
First Lien Debt / Adj. EBITDA |
1.6x |
|
2.2x |
|
2.9x |
|
3.5x |
|
4.8x |
||||||||||
Net Debt / Adj. EBITDA |
3.8x |
|
4.9x |
|
6.6x |
|
7.6x |
|
10.3x |
||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240209514248/en/
Investor:
Catalent, Inc.
Paul Surdez
732-537-6325
investors@catalent.com
Source: Catalent, Inc.
FAQ
What was Catalent's net revenue in Q2'24?
What was the net loss in Q2'24 compared to Q2'23?
What was the Adjusted EBITDA in Q2'24?
How much did Catalent raise in term loans?
Who is acquiring Catalent?
